Xigduo is the first fixed-dose combination to receive regulatory approval. It combines in twice daily tablet Forxiga, a SGLT2 inhibitor that lessens the reabsorption of excess glucose, and metformin, the standard drug for treating the disease.
The tablet is used in suffering adults as an addition to the diet and exercise which improves glycaemic control.
380m people worldwide are affected by type 2 diabetes, and its projected to reach 595m by 2035. It accounts for 85 per cent to 95 per cent of all cases of diagnosed diabetes in adults.